Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Filings indexed 747 across all filing types
Latest filing 2021-10-05 Regulatory Filings
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
D&O Disclosure - NZX - Darling - Suttie - Gallaher 8 pages 503.7KB
Regulatory Filings
2021-10-05 English
Capital Change Notice
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Pacific Edge Limited Capital Change Notice' and details the issuance of 750,000 ordinary shares at $0.80 per share, including specifics such as the total number of shares after issuance, authority for the issue, and date of issue. It is a formal announcement of a capital change event, specifically a share issue due to exercise of options. The document length is short (3026 characters) and contains no financial statements or detailed financial analysis. It is not an annual or interim report, nor an earnings release or management discussion. The content fits the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital structure changes.
2021-10-05 English
D&O Ongoing Disclosure – David Darling
Regulatory Filings
2021-10-05 English
D&O Ongoing Disclosure - David Darling - NZX 2 pages 188.0KB
Regulatory Filings
2021-10-04 English
Application for quotation of securities - PEB 6 pages 28.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary shares. It includes specifics about the number of securities, issue dates, and whether the securities are part of an employee incentive scheme. This is a clear announcement related to new securities being issued and quoted, which fits the category of Share Issue/Capital Change filings. The document is not a financial report, earnings release, or management discussion, but rather a formal notification of capital changes due to option exercises and securities issuance.
2021-10-04 English
Capital Change Notice
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Pacific Edge Limited Capital Change Notice' and details the issuance of ordinary shares, including the number of shares issued, prices, and authority for the issue. It specifies that shares were issued on exercise of options and includes detailed capital change information. The document length is 3081 characters, which is relatively short and focused solely on capital changes. There is no indication of full financial statements or comprehensive financial reporting. This fits the definition of a 'Share Issue/Capital Change' announcement rather than a full report or other filing type.
2021-10-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.